Seattle Genetics begins combination trial of SGN-35 plus ABVD

chemo treatment NCI.jpg

Seattle Genetics and Millennium Pharmaceuticals have announced the initiation of a Phase I multi-center clinical trial of their highly anticipated antibody-drug conjugate brentuximab vedotin in combination with the ABVD chemotherapy regimen, widely regarded as the gold standard in the treatment of Hodgkin's lymphoma.

Brentuximab vedotin (formerly known as SGN-35), which targets the CD30 protein on cancer cells, is currently in a trio of single-agent clinical trials:

- A clinical trial conducted under a Special Protocol Assessment (SPA) with the FDA for relapsed or refractory Hodgkin's lymphoma;
- A Phase II trial for relapsed or refractory systemic anaplastic large cell lymphoma;
- A Phase II retreatment trial for relapsed patients who previously responded to the therapy.

Additionally, a phase III relapse prevention trial is scheduled to be initiated by summer of 2010 for post-transplant Hodgkin's patients.

By Ross Bonander

LymphomaInfo Social